Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Maria Font Pous"'
Autor:
Anna, Martini, Laura, Pivetta, Francesca, Schmid, Andrea, Ossato, Liana Dal Mas, Michele, Caeran, Antonella, Scandola, Realdon, Nicola, Maria Font Pous, Roberta, Joppi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3657::5e90fa78353ef17bad11d8ae71cf3afe
https://hdl.handle.net/11577/3474118
https://hdl.handle.net/11577/3474118
Autor:
David Phizackerley, Jean Louis Montastruc, Wolf-Dieter Ludwig, Maria Font-Pous, Juan Erviti, Giulio Formoso, Blanka Pospíšilová, Dick Bijl
Publikováno v:
Health Policy. 121:257-264
Purpose To evaluate the framework of drug information produced by public health and regulatory institutions in Europe. Materials and methods We carried out a short survey asking editors of ISDB bulletins of the European region to indicate the main so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef2537b094ad22464cfcb5befee8c504
https://doi.org/10.1016/j.healthpol.2016.12.007
https://doi.org/10.1016/j.healthpol.2016.12.007
Autor:
Giulio, Formoso, Maria, Font Pous
Publikováno v:
Recenti progressi in medicina. 108(2)
Information on added therapeutic value of medicines should represent the basis for therapeutic decisions and ideally, before of that, for drug registration. A recent study assessed the availability and quality of such information provided by Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::18ccece4386bc87ea8f3a281043a6ce4
https://pubmed.ncbi.nlm.nih.gov/28287200
https://pubmed.ncbi.nlm.nih.gov/28287200
Publikováno v:
European Journal of Clinical Pharmacology
European Journal of Clinical Pharmacology, Springer Verlag, 2010, 66 (8), pp.785-790. ⟨10.1007/s00228-010-0848-8⟩
European Journal of Clinical Pharmacology, Springer Verlag, 2010, 66 (8), pp.785-790. ⟨10.1007/s00228-010-0848-8⟩
In 2005, new European legislation authorised Regulatory Agencies to require drug companies to submit a risk management plan (RMP) comprising detailed commitments for post-marketing pharmacovigilance. The aim of the study is to describe the characteri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfe1c999bd0f756a0653dfb0f4a40799
http://hdl.handle.net/11562/344010
http://hdl.handle.net/11562/344010
Autor:
Anita Conforti, Serena Frau, Marco Camporese, Maria Font Pous, Guido Giustetto, Alessandro Nobili, Giuseppe Lombardo, Francesco DelZotti, Roberta Zimol, Luigi Mezzalira, Giulia Zermiani
Publikováno v:
Scopus-Elsevier
Journal of Innovation in Health Informatics, Vol 18, Iss 2, Pp 109-116 (2010)
Journal of Innovation in Health Informatics, Vol 18, Iss 2, Pp 109-116 (2010)
Background Many different brands of primary care electronic patient record (EPR) software are available to general practitioners (GPs). Their ability to support GPs in improving prescribing varies greatly. Objective To assess, using a ten-item tool,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b4ebc836542facb11f7a3ca66762038
http://www.scopus.com/inward/record.url?eid=2-s2.0-78449303231&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-78449303231&partnerID=MN8TOARS